-
公开(公告)号：US09562090B2
公开(公告)日：2017-02-07
申请号：US13763768
申请日：2013-02-11
申请人： Domantis Limited
CPC分类号： C07K16/2878 , A61K9/007 , A61K9/0078 , A61K9/1623 , A61K9/1641 , A61K39/3955 , A61K2039/544 , A61M11/005 , A61M15/08 , A61M16/14 , C07K16/00 , C07K16/005 , C07K16/22 , C07K16/2866 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/64 , C07K2317/73 , C07K2317/76 , C07K2317/90 , C07K2317/92 , C07K2317/94
摘要： The invention relates to anti-TNFR1 polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for as therapeutics and/or prophylactics that are likely to encounter proteases when administered to a patient, for example for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating inflammatory disease, such as arthritis or COPD.
摘要翻译： 本发明涉及抗TNFR1多肽和抗蛋白酶降解的抗体单可变结构域（dAb），以及包含它们的拮抗剂。 多肽，dAb和拮抗剂可用作当被施用于患者时可能遇到蛋白酶的治疗剂和/或预防剂，例如用于肺部给药，口服给药，递送至肺部并递送至患者的胃肠道， 以及用于治疗炎性疾病，例如关节炎或COPD。
-
公开(公告)号：US20170174775A1
公开(公告)日：2017-06-22
申请号：US15386141
申请日：2016-12-21
申请人： Domantis Limited
IPC分类号： C07K16/28 , A61K9/16 , A61M15/08 , C07K16/00 , C07K16/22 , A61M11/00 , A61K39/395 , A61K9/00
CPC分类号： C07K16/2878 , A61K9/007 , A61K9/0078 , A61K9/1623 , A61K9/1641 , A61K39/3955 , A61K2039/544 , A61M11/005 , A61M15/08 , A61M16/14 , C07K16/00 , C07K16/005 , C07K16/22 , C07K16/2866 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/64 , C07K2317/73 , C07K2317/76 , C07K2317/90 , C07K2317/92 , C07K2317/94
摘要： The invention relates to anti-TNFR1 polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for as therapeutics and/or prophylactics that are likely to encounter proteases when administered to a patient, for example for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating inflammatory disease, such as arthritis or COPD.
-
公开(公告)号：US20140141093A1
公开(公告)日：2014-05-22
申请号：US13763768
申请日：2013-02-11
申请人： Domantis Limited
CPC分类号： C07K16/2878 , A61K9/007 , A61K9/0078 , A61K9/1623 , A61K9/1641 , A61K39/3955 , A61K2039/544 , A61M11/005 , A61M15/08 , A61M16/14 , C07K16/00 , C07K16/005 , C07K16/22 , C07K16/2866 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/64 , C07K2317/73 , C07K2317/76 , C07K2317/90 , C07K2317/92 , C07K2317/94
摘要： The invention relates to anti-TNFR1 polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for as therapeutics and/or prophylactics that are likely to encounter proteases when administered to a patient, for example for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating inflammatory disease, such as arthritis or COPD.
摘要翻译： 本发明涉及抗TNFR1多肽和抗蛋白酶降解的抗体单可变结构域（dAb），以及包含它们的拮抗剂。 多肽，dAb和拮抗剂可用作当被施用于患者时可能遇到蛋白酶的治疗剂和/或预防剂，例如用于肺部给药，口服给药，递送至肺部并递送至患者的胃肠道， 以及用于治疗炎性疾病，例如关节炎或COPD。
-
公开(公告)号：US10072089B2
公开(公告)日：2018-09-11
申请号：US15386141
申请日：2016-12-21
申请人： Domantis Limited
IPC分类号： A61K39/395 , C07K16/28 , A61K9/16 , A61K9/00 , C07K16/00 , C07K16/22 , A61M11/00 , A61M15/08
CPC分类号： C07K16/2878 , A61K9/007 , A61K9/0078 , A61K9/1623 , A61K9/1641 , A61K39/3955 , A61K2039/544 , A61M11/005 , A61M15/08 , A61M16/14 , C07K16/00 , C07K16/005 , C07K16/22 , C07K16/2866 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/64 , C07K2317/73 , C07K2317/76 , C07K2317/90 , C07K2317/92 , C07K2317/94
摘要： The invention relates to anti-TNFR1 polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for as therapeutics and/or prophylactics that are likely to encounter proteases when administered to a patient, for example for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating inflammatory disease, such as arthritis or COPD.
-
公开(公告)号：US20190040148A1
公开(公告)日：2019-02-07
申请号：US16047197
申请日：2018-07-27
申请人： Domantis Limited
IPC分类号： C07K16/28 , C07K16/22 , A61K9/00 , A61K9/16 , A61K39/395 , A61M11/00 , A61M15/08 , A61M16/14 , C07K16/00 , A61K39/00
摘要： The invention relates to anti-TNFR1 polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for as therapeutics and/or prophylactics that are likely to encounter proteases when administered to a patient, for example for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating inflammatory disease, such as arthritis or COPD.
-
-
-
-
搜索结果
5 条记录 (耗时 0.026 秒)
